Health & Medicine
Table of Contents
1. What are GLP-1 medications?
2. How do they work for weight loss?
3. Available GLP-1 drugs in 2025–2026
4. Who qualifies?
5. How much weight can you lose?
6. Side effects and safety
7. How to get started
8. Trusted resources
9. Conclusion
10.Frequently Asked Questions
| 30M+ Americans using GLP-1s for weight loss in 2025 | ~20% Average body weight loss with tirzepatide at 72 weeks | 1B+ People worldwide living with obesity | 40+ New GLP-1 compounds currently in development |
What are GLP-1 medications?
GLP-1 stands for glucagon-like peptide-1, a hormone your gut naturally releases after you eat. It signals the pancreas to release insulin, slows the movement of food through your digestive system, and—crucially—tells your brain that you’re full.
GLP-1 receptor agonists are synthetic drugs that mimic this hormone. They were originally developed to treat type 2 diabetes, but researchers quickly realized that reduced appetite was a powerful secondary effect, making them highly effective tools for long-term weight management.
In December 2025, the World Health Organization (WHO) added GLP-1 therapies to its Essential Medicines List for managing obesity — a landmark endorsement that signals these drugs have moved firmly into mainstream medicine.
GLP-1 Injection Pen — Semaglutide / Tirzepatide
GLP-1 medications like Wegovy (semaglutide) are administered as once-weekly subcutaneous injections. A daily pill form became available in late 2025.
How do GLP-1 drugs work for weight loss?
GLP-1 medications tackle weight from multiple biological angles simultaneously, which is why they outperform older diet drugs.
- Slow gastric emptying—food stays in your stomach longer, keeping you physically full for extended periods after meals.
- Suppress appetite signals in the brain—the hypothalamus receives “full” signals even when you’ve eaten less than usual.
- Regulate blood sugar—By stimulating insulin release and suppressing glucagon, these drugs smooth out blood sugar spikes that can trigger hunger.
- Reduce cravings—many patients report a dramatic reduction in “food noise,” the constant mental preoccupation with eating.
- Improve metabolic health—lower blood pressure, better cholesterol, and reduced cardiovascular risk are well-documented benefits beyond weight loss itself.
Available GLP-1 drugs in 2025–2026
The landscape has expanded significantly. Here are the major approved options:
| Wegovy Injection Semaglutide 2.4mg — Novo Nordisk FDA-approved since 2021. Once-weekly injection. Approved for adults (BMI ≥30 or ≥27 with comorbidity) and children 12+. Average weight loss: ~15% body weight. | Wegovy Pill Oral Oral semaglutide 25mg — Novo Nordisk FDA-approved December 2025. The first oral GLP-1 approved for obesity. Once-daily. Clinical trials showed ~13.6% weight reduction at 71 weeks. |
| Zepbound Injection Tirzepatide — Eli Lilly FDA-approved for obesity in 2023. Dual GLP-1/GIP agonist. Highest documented weight loss (~20–22%) of any approved drug. Once-weekly injection. | Saxenda Injection Liraglutide 3mg — Novo Nordisk An older GLP-1 approved for obesity. Daily injection. Effective but less weight loss than newer options (~5–8%). Often a stepping stone or alternative. |
Looking ahead: Eli Lilly’s orforglipron—an oral pill—completed phase 3 trials in 2025, showing 11.2% weight loss at the 36 mg dose at 72 weeks, and is awaiting FDA approval. Their injectable retatrutide (triple receptor agonist) is also in phase 3 trials with early results suggesting even greater efficacy than tirzepatide.
Who qualifies for GLP-1 weight loss medications?
FDA approval covers adults who meet either of these criteria:
- A Body Mass Index (BMI) of 30 or higher (classified as obesity)
- A BMI of 27 or higher with at least one weight-related health condition — such as high blood pressure, high cholesterol, sleep apnea, or type 2 diabetes
Your prescribing physician will also review your full medical history, prior weight-loss attempts, family history, and current medications before deciding whether a GLP-1 is appropriate for you. GLP-1 drugs are generally not recommended during pregnancy, for people with a history of pancreatitis, or for those with certain thyroid conditions (medullary thyroid carcinoma or MEN2).
Important note: These medications are not intended for casual use or modest weight goals. They are approved treatments for a chronic medical condition and should be prescribed and monitored by a licensed healthcare provider.
How much weight can you realistically lose?
Clinical trial results vary by drug and individual, but the numbers are substantial compared to older obesity medications:
| ~15% Average loss with Wegovy (semaglutide injection) over 68 weeks | ~22% Average loss with Zepbound (tirzepatide) at highest dose, 72 weeks | ~14% Average loss with oral Wegovy pill at 71 weeks (OASIS 4 trial) | ~11% Average loss with oral orforglipron at highest dose, 72 weeks |
For context, a 15% reduction in body weight for someone at 250 lbs means losing roughly 37 pounds. These are averages — individual results depend on adherence, diet, exercise, and metabolism. People who combine medication with nutritional counseling and physical activity consistently achieve better outcomes.
One critical caveat: research consistently shows that most people regain a substantial portion of lost weight after stopping the medication. This means GLP-1 therapy is generally considered long-term treatment, not a short course.
Side effects and safety
GLP-1 medications are considered safe when used under medical supervision, but they do carry side effects — most of which are gastrointestinal and tend to lessen over time as the body adjusts.
Common side effects
Nausea (most common) Vomiting Headache Dizziness | Constipation or diarrhea Abdominal discomfort Fatigue Forgetting to eat (yes, really) |
Gastrointestinal issues account for roughly half of all side effects reported for these drugs. Clinicians typically manage this by starting at the lowest possible dose and increasing slowly—no faster than once per month.
Rare but serious risks
In January 2026, the UK’s MHRA issued updated safety guidance highlighting the risk of acute pancreatitis. There are also very rare reports of a specific eye condition (non-arteritic anterior ischemic optic neuropathy) affecting approximately 1 in 10,000 users of semaglutide. Eye disorder signals are being actively monitored by regulators. Earlier concerns about suicidal ideation were reviewed and found unsupported by current data.
How to get started with GLP-1 medications
- Talk to your primary care physician, endocrinologist, or obesity medicine specialist about whether you qualify based on your BMI and health profile.
- Have a full medical history review — including any contraindications like pancreatitis history, thyroid conditions, or pregnancy.
- Get a prescription and discuss which drug is right for you—injection vs. pill, weekly vs. daily—based on preference and tolerability.
- Start at the lowest dose. Your provider will titrate upward slowly over several months to minimize side effects.
- Pair medication with lifestyle changes — work with a dietitian and exercise physiologist for the best and most sustainable outcomes.
- Plan for the long term. Discuss with your provider what a tapering or maintenance strategy looks like if you ever decide to stop.
Conclusion
GLP-1 receptor agonists represent a genuine turning point in how medicine approaches obesity. For the first time, people living with this chronic condition have access to medications that don't just suppress appetite short-term—they address the underlying hormonal and neurological drivers of weight gain.
From injectable semaglutide and tirzepatide to the newly approved oral Wegovy pill, the options are expanding. The WHO's 2025 endorsement and inclusion on the Essential Medicines List signals that the global medical community has recognized these drugs as legitimately important tools—not fads.
That said, they are not a cure-all. The best outcomes come from combining medication with dietary guidance, physical activity, and long-term medical support. And because weight often returns after stopping, anyone starting GLP-1 therapy should think of it as a long-term commitment, just as one would with blood pressure or cholesterol medication.
If you think GLP-1 treatment may be right for you, start by speaking honestly with your doctor about your health history, goals, and what you're willing to commit to.
Sources:
World Health Organization (2025) · Obesity Medicine Association (2026) · Yale Medicine (2026) · AAMC News (2026) · The Pharmaceutical Journal (2026) · Intermountain Health · Scientific American (2026) · JAMA / WHO Guideline Publication
